Table 1.
NLRP3 and GSDMD-N protein expression in breast cancer and their relationship with clinically relevant parameters.
| NLRP3 | GSDMD-N | |||||
|---|---|---|---|---|---|---|
| Low expression | High expression | P-value | Low expression | High expression | P-value | |
| Age (years) | ||||||
| <50 | 22 (48.89%) | 23 (51.11%) | .673 | 22 (48.89%) | 23 (51.11%) | .398 |
| ≥50 | 20 (44.44%) | 25 (55.56%) | 26 (57.78%) | 19 (42.22%) | ||
| Pathological grade | ||||||
| I | 2 (16.67%) | 10 (83.33%) | .001 | 4 (33.33%) | 8 (66.67%) | .002 |
| II | 23 (40.35%) | 34 (59.65%) | 26 (45.61%) | 31 (54.39%) | ||
| III | 17 (80.95%) | 4 (19.05%) | 18 (85.71%) | 3 (14.29%) | ||
| Tumor size | ||||||
| <2 cm | 5 (26.32%) | 14 (73.68%) | .045 | 6 (31.58%) | 13 (68.42%) | .032 |
| ≥2 cm | 37 (52.11%) | 34 (47.89%) | 42 (59.15%) | 29 (40.85%) | ||
| Lymph node metastasis | ||||||
| No | 13 (31.71%) | 28 (68.29%) | .009 | 16 (39.02%) | 25 (60.98%) | .013 |
| Yes | 29 (59.18%) | 20 (40.82%) | 32 (65.31%) | 17 (34.69%) | ||
| Pathological TNM grade | ||||||
| I | 11 (31.43%) | 24 (68.57%) | .011 | 11 (31.43%) | 24 (68.57%) | .001 |
| II | 29 (54.72%) | 24 (45.28%) | 35 (66.04%) | 18 (33.96%) | ||
| III | 2 (100.00%) | 0 (0.00%) | 2 (100.00%) | 0 (0.00%) | ||
GSDMD-N = gasdermin D N-terminal, NLRP3 = nucleotide-binding oligomerization domain-like receptor protein 3.